freepeople性欧美熟妇, 色戒完整版无删减158分钟hd, 无码精品国产vα在线观看DVD, 丰满少妇伦精品无码专区在线观看,艾栗栗与纹身男宾馆3p50分钟,国产AV片在线观看,黑人与美女高潮,18岁女RAPPERDISSSUBS,国产手机在机看影片

正文內(nèi)容

乳腺癌的內(nèi)科治療-資料下載頁

2025-01-02 17:04本頁面
  

【正文】 AntiHER1, HER2, HER4tyrosine kinase inhibitors(ZD1839,OSI774,EKB569,GW2023,CI1033)RAS farnesyl transferase inhibitors (BMS214662,R115777)RAF inhibitors(BAY439006)MEK inhibitors(CI1040)mTOR inhibitors(CCI779,RAD001)Targeted therapies in breast cancer SosSos Herceptin與化療藥物的協(xié)同作用–協(xié)同作用 : 鉑類多西紫杉醇去甲長春花堿放療–迭加作用 : 阿霉素紫杉醇環(huán)磷酰胺–拮抗作用 : 5FluorouracilHercetpin單藥治療晚期乳腺癌的療————————————————————— HO649g HO551g HO650 ( 關(guān)鍵試驗(yàn)) ( Ⅱ 期) (關(guān)鍵試驗(yàn))_____________________________________________n(intenttotreat) 222 46 114 CR 8 1 7 PR 26 4 23 有效率 15% 11% 26%中位緩解期(月) 中位生存期(月) 13 14 ______________________________________________晚期乳腺癌應(yīng)用化療 ?Herceptin的結(jié)果( Slamon et al. Proc ASCO, 1998)EGF100151 Study Design? Progressive, HER2+ MBC or LABC ? Previously treated with anthracycline, taxane and trastuzumab ? No prior capecitabine? Measurable disease by RECIST? LVEF ≥ institution LLN Lapatinib 1250 mg po qd continuously + Capecitabine 2023 mg/m2/d po days 114 q 3 wk Capecitabine 2500 mg/m2/d po days 114 q 3 wkPts on treatment until progression or unacceptable toxicity, then followed for survivalStratification:? Disease sites? Stage of diseaseCameron et al. ESMO 2023.Randomized N=324 (Nov 15 2023)RANDOMIZATIONTime to Progression (TTP) Based on Independent Review0 10 20 30 40 50 60Time (weeks)70 Pvalue (logrank, 1sided)72 (45%)49 (30%)Progressed or died (, )Hazard ratio (95% CI) ( mo) ( mo)Median TTP, wk161163No. of ptsCapecitabineLapatinib + CapecitabineCumulative ProgressionFree SurvivalProgressionFree Survival (PFS) Based on Independent Review0 10 20 30 40 50 60Time (weeks)70 Pvalue (logrank, 1sided)76 (47%)49 (30%)Progressed or died (, )Hazard ratio (95% CI) ( mo) ( mo)Median PFS, wk161163No. of ptsCapecitabineLapatinib + CapecitabineCumulative ProgressionFree SurvivalE2100: A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as FirstLine Therapy for Locally Recurrent or Metastatic BCaASCO 2023分層 :? DFI 24 mos. vs. 24 mos.? 3 vs. 3 metastatic sites? Adjuvant chemotherapy yes vs. no? ER+ vs. ER vs. ER unknownRANDOMIZE 紫杉醇周療 + Bevacizumab(貝伐單抗 )紫杉醇周療研究設(shè)計(jì)研究設(shè)計(jì)28day cycle: 紫杉醇 90 mg/m2 D1, 8 and 15Bevacizumab 10 mg/kg D1 and 15E2100: 緩解率緩解率316 236330 250%%%%P所有患者 可測(cè)量疾病010203040紫杉醇周療Overall Response Rate紫杉醇周療 +BevE2100: 無進(jìn)展生存無進(jìn)展生存HR = ()Log Rank Test pMonthsPFS Proportion0 10 20 30紫杉醇周療 + Bev. 紫杉醇周療 月E2100:總生存總生存0 10 20 30 40MonthsOS Proportion紫杉醇周療 + Bev. 紫杉醇周療 HR = ()Log Rank Test p=Bevacizumab 毒性毒性NCICTC Grade 3 and 4紫杉醇周療(n=330)紫杉醇周療 + Bev.(n=342)%Grade 3 Grade 4 Grade 3 Grade 4高血壓 * 0 0 13 血栓栓塞 0出血 0 0 蛋白尿 ** 0 0 NCICTC , worst per patient *p。**p=其它毒性其它毒性NCICTC Grade 3 and 4紫杉醇周療(n=330)紫杉醇周療 + Bev.(n=342)%Grade 3 Grade 4 Grade 3 Grade 4神經(jīng)毒性 * 虛弱 0 中性粒細(xì)胞減少 0 3 ? LVEF 0 0 0NCICTC , worst per patient *p=結(jié)論結(jié)論l 將 bevacizumab (貝伐單抗 )加入到紫杉醇周療中治療 MBCu 明顯延長了無進(jìn)展生存u 提高了客觀緩解率u 需要更長的隨訪以評(píng)估對(duì)總生存的影響l 需要進(jìn)一步研究以識(shí)別最可能從 VEGF靶向治療中獲益的患者個(gè)體化治療( Tailored Therapy)化療 化療 化療Recurrence Score (RS) Algorithm 31High risk 18 and 31Intermediate risk 18Low riskRecurrence Score (RS)CategoryScale:0to100PaikS,etal:SABCS2023Sensitivity ( + )Sensitivity ( )Responder Probable survival benefitNonRespondersToxicity without survival benefitDelay in effectivetreatment Anticancer agentToday One Size Fits All TherapySensitivity ( + )Sensitivity ( )ResponderSurvival benefitNonRespondersToxicity without survival benefitDelay in effectivetreatment The Future Tailored TherapyMolecularprofiling 1 2 2Righttherapyforrightpatient 3晚期乳腺癌內(nèi)科治療共識(shí)l 晚期乳腺癌的主要治療目的是提高患者的生活質(zhì)量,延長高質(zhì)量的生存期。l 化療、內(nèi)分泌治療和生物靶向治療是治療晚期乳腺癌的同樣有效的治療方法,但分別有各自的適應(yīng)證l 通過合理的內(nèi)科治療,能顯著延長患者的生存期,部分患者甚至能夠長期生存。謝謝!Tel:010-- 87788226 或或 87788120Email:謝謝謝謝 ??!謝謝觀看 /歡迎下載BY FAITH I MEAN A VISION OF GOOD ONE CHERISHES AND THE ENTHUSIASM THAT PUSHES ONE TO SEEK ITS FULFILLMENT REGARDLESS OF OBSTACLES. BY FAITH I BY FAITH
點(diǎn)擊復(fù)制文檔內(nèi)容
教學(xué)課件相關(guān)推薦
文庫吧 www.dybbs8.com
備案圖鄂ICP備17016276號(hào)-1